你目前无法使用部分二次筛选功能
请联系客服开通更多权限和功能！
| 药品名称 | 剂型 | USP 溶出方法 | 转速（转/min） | 溶出介质 | 容积 | 推荐采样时间 | 更新时间 | 查看详情 |
|---|---|---|---|---|---|---|---|---|
| Dexamethasone | Implant (Intravitreal) | Develop a method to characterize in vitro release | 2026-08-19 | 查看 | ||||
| Meloxicam | Orally Disintegrating Tablets | II (Paddle) | 25 | 0.2 M Phosphate Buffer, pH 7.5 | 900 | 3, 5, 10, 15 and 20 | 2026-08-19 | 查看 |
| Ruxolitinib | Tablet (Extended Release) | I (Basket) | 75 | 20 mM potassium phosphate buffer, pH 6.8 | 900 | 1, 2, 4, 6, 8, 12, 16, 20 and 24 hours | 2026-08-06 | 查看 |
| Ensitrelvir | Tablet | II (Paddle) | 50 | 0.1 N HCl with 0.1% SLS | 900 | 5, 10, 15, 20, 30, 45 and 60 | 2026-08-06 | 查看 |
| Tebipenem Pivoxil | Tablet | II (Paddle) | 50 | pH 5.5 acetate buffer | 900 | 5, 10, 15, 20, 30, 45 and 60 | 2026-08-06 | 查看 |
| Baxdrostat | Tablet | Refer to FDA's Dissolution Guidance, 2018 | 2026-08-06 | 查看 | ||||
| Doravirine/Islatravir | Tablet | II (Paddle) | 75 | 25 mM phosphate buffer, pH 6.2 with 75 mM NaCl and 1.5% polyoxyethylene (23) lauryl ether | 900 | 5, 10, 15, 20, 30, 45 and 60 | 2026-08-06 | 查看 |
| Vepdegestrant | Tablet | II (Paddle) | 75 | pH 6.8 buffer with 1.75% Tween 80 | 900 | 5, 10, 15, 20, 30, 45 and 60 | 2026-08-06 | 查看 |
| Tafenoquine Succinate [EQ 100 mg base] | Tablet | II (Paddle) | 50 | pH 3.2 ± 0.1 acetate buffer | 500 | 5, 10, 15, 20, 30, 45, 60, 75, 90, 120 and 150 | 2026-08-06 | 查看 |
| Cobicistat (Cobi)/Darunavir Ethanolate (DE) | Tablet (For Suspension) | II (Paddle) | 75 | Cobi: Citrate Phosphate Buffer, pH 4.2; DE: 0.05 M Sodium Phosphate Buffer, pH 3.0 with 2.0% (w/v) Tween 20 | 900 | 5, 10, 15, 20, 30, 45 and 60 | 2026-05-22 | 查看 |
